Aripiprazole is the antipsychotic least likely to decrease sodium and should be considered for your patient with a sodium of 131 mmol/L.
Based on the most recent and highest quality evidence, aripiprazole demonstrates a significantly lower risk of hyponatremia compared to other second-generation antipsychotics, making it the preferred choice for patients with existing hyponatremia.
Evidence Supporting Aripiprazole
A 2026 retrospective cohort study analyzing 55,394 patients found that aripiprazole was associated with a 48% lower risk of hyponatremia compared to olanzapine (adjusted hazard ratio 0.52; 95% CI 0.35-0.76) 1. This finding was consistent across multiple databases including FDA adverse event reports and Japanese claims data, with sensitivity analyses confirming robustness.
Importantly, a 2023 French guideline on hepatic encephalopathy noted that while benzodiazepines and opioids were independently associated with increased risk of hepatic encephalopathy, this association was not found for antipsychotics 2. This suggests antipsychotics as a class may be safer than other psychotropic medications in vulnerable populations with electrolyte disturbances.
Clinical Context for Your Patient
With a sodium of 131 mmol/L, your patient falls into a critical threshold where:
- Hyponatremia should be further investigated and treated when serum sodium is <131 mmol/L 3
- This level is associated with symptoms including general weakness, confusion, headache, and nausea 4
- In cirrhotic patients specifically, sodium <130 mmol/L is an independent risk factor for hepatic encephalopathy and non-response to lactulose 2
Antipsychotics to Avoid
While aripiprazole shows the lowest risk, most other second-generation antipsychotics showed higher reporting odds ratios for hyponatremia in the FAERS database 1. Recent reviews confirm that antipsychotics as a drug class are associated with drug-induced hyponatremia 5, 6, though the mechanism and risk vary by agent.
Important Caveats
Drug-induced hyponatremia typically occurs shortly after treatment initiation 6. Therefore, if switching to aripiprazole:
- Monitor sodium levels closely in the first few weeks
- Evaluate for other contributing factors (diuretics, SSRIs, anticonvulsants, PPIs, carbamazepine)
- Assess volume status and consider underlying conditions (SIADH, cerebral salt wasting, cirrhosis)
- Address any precipitating factors like infections, which can independently cause hyponatremia
The comparative safety of aripiprazole makes it the evidence-based choice for patients requiring antipsychotic therapy who have baseline hyponatremia or are at high risk for developing it.